Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Neoplasm Metastasis 2Nasopharyngeal Carcinoma 1Advanced Solid Tumor 1Advanced Malignant Tumors 1

Interventions

pembrolizumab 59Gemcitabine 37Biopsy 33Specimen Handling 32Paclitaxel 30Magnetic Resonance Spectroscopy 30Nivolumab 29Cisplatin 26Carboplatin 25Irinotecan 24Cyclophosphamide 23Fluorouracil 22Bevacizumab 22Docetaxel 21Oxaliplatin 19Leucovorin 18Ipilimumab 17Cetuximab 17Capecitabine 17130-nm albumin-bound paclitaxel 16Everolimus 15Albumin-Bound Paclitaxel 15Trastuzumab 13olaparib 12Pemetrexed 12Erlotinib Hydrochloride 12spartalizumab 11Sorafenib 11Radiosurgery 11trastuzumab deruxtecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasm Metastasis × SHR-1701 × Clear all
NCT03774979 2022-11-08

SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
193 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03710265 2021-11-22

SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
206 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡